39. Fibrodysplasia ossificans progressive: A case report and literature review
Main Article Content
Abstract
Progressive Fibrodysplasia Ossificans (FOP) is a rare autosomal dominant genetic disorder that gradually causes ossification of muscles, tendons, ligaments, and other fibrous tissues. The disease begins in early childhood, leading to limb and trunk deformities. Surgical interventions can trigger ossification and should be contraindicated. We report a case of a 3.5-year-old boy treate at the National Children's Hospital. The child presented with tumors in the nape and lumbar region, as well as abdominal swelling without fever or signs of significant inflammation. Both great toes were abnormally short and inwardly curved. After tumor excision, the surgical site developed fibrosis with a firm scar. Blood tests, including hematology, biochemistry, calcium, and vitamin D, were normal. X-rays revealed spinal scoliosis and abnormal bone growth. Histopathological examination showed fatty tissue, collagen bundles, fibroblasts, and multiple ossified areas. Genetic analysis identified a pathogenic heterozygous dominant variant in ACVR1: c.617G>A (p.Arg206His). FOP diagnosis is based on clinical features, particularly great toe malformations, and genetic analysis. Invasive procedures should be avoided to prevent ossification activation.
Article Details
Keywords
Fibrodysplasia ossificans progressiva, great toe deformities, heterotopic ossification
References
2. Shore EM, Xu M, Feldman GJ, et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet. 2006; 38(5): 525-527. doi:10.1038/ng1783.
3. Liljesthröm M, Pignolo R, Kaplan F. Epidemiology of the Global Fibrodysplasia Ossificans Progressiva (FOP) Community. J Rare Dis Res Treat. 2020; 5(2): 31-36. doi:10.29245/2572-9411/2020/2.1196.
4. Akesson LS, Savarirayan R. Fibrodysplasia Ossificans Progressiva. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, eds. GeneReviews®. University of Washington, Seattle; 1993. Accessed December 10, 2024. http://www.ncbi.nlm.nih.gov/books/NBK558090/.
5. Agrawal U, Tiwari V. Fibrodysplasia Ossificans Progressiva. In: StatPearls [Internet]. StatPearls Publishing; 2023. Accessed February 7, 2025. https://www.ncbi.nlm.nih.gov/books/NBK576373/.
6. Pignolo RJ, Shore EM, Kaplan FS. Fibrodysplasia Ossificans Progressiva: Diagnosis, Management, and Therapeutic Horizons. Published online 2014.
7. Qi Z, Luan J, Zhou X, Cui Y, Han J. Fibrodysplasia ossificans progressiva: Basic understanding and experimental models. Intractable Rare Dis Res. 2017; 6(4): 242-248. doi:10.5582/irdr.2017.01055.
8. Kitoh H. Clinical Aspects and Current Therapeutic Approaches for FOP. Biomedicines. 2020; 8(9): 325. doi:10.3390/biomedicines8090325.
9. Shaikh U, Khan A, Kumari P, et al. Novel Therapeutic Targets for Fibrodysplasia Ossificans Progressiva: Emerging Strategies and Future Directions. Cureus. Published online July 28, 2023. doi:10.7759/cureus.42614.
10. Pacifici M, Shore EM. Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders. Cytokine & Growth Factor Reviews. 2016; 27: 93-104. doi:10.1016/j.cytogfr.2015.12.007.
11. Katagiri T, Tsukamoto S, Nakachi Y, Kuratani M. Recent Topics in Fibrodysplasia Ossificans Progressiva. Endocrinol Metab. 2018; 33(3): 331. doi:10.3803/EnM.2018.33.3.331.
12. Valer JA, Sánchez-de-Diego C, Pimenta-Lopes C, Rosa JL, Ventura F. ACVR1 Function in Health and Disease. Cells. 2019; 8(11): 1366. doi:10.3390/cells8111366.
13. Pignolo RJ, Baujat G, Brown MA, et al. The natural history of fibrodysplasia ossificans progressiva: A prospective, global 36-month study. Genetics in Medicine. 2022; 24(12): 2422-2433. doi:10.1016/j.gim.2022.08.013.
14. Kitterman JA, Kantanie S, Rocke DM, Kaplan FS. Iatrogenic Harm Caused by Diagnostic Errors in Fibrodysplasia Ossificans Progressiva. Pediatrics. 2005; 116(5): e654-e661. doi:10.1542/peds.2005-0469.
15. Smilde B, Botman E, De Ruiter R, et al. Monitoring and Management of Fibrodysplasia Ossificans Progressiva: Current Perspectives. ORR. 2022; Volume 14: 113-120. doi:10.2147/ORR.S337491.